{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T04:33:55Z","timestamp":1771475635715,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s12325-017-0500-4","type":"journal-article","created":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T14:09:12Z","timestamp":1488377352000},"page":"937-953","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Retrospective Study on the Impact of Adherence in Achieving Glycemic Goals in Type 2 Diabetes Mellitus Patients Receiving Canagliflozin"],"prefix":"10.1007","volume":"34","author":[{"given":"Erin K.","family":"Buysman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaffeeulah","family":"Bacchus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mike","family":"Ingham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,3,1]]},"reference":[{"key":"500_CR1","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.2337\/dc14-1036","volume":"37","author":"TM Dall","year":"2014","unstructured":"Dall TM, Yang W, Halder P, et al. The economic burden of elevated blood glucose levels in 2012: diagnosed and undiagnosed diabetes, gestational diabetes mellitus, and prediabetes. Diabetes Care. 2014;37:3172\u20139.","journal-title":"Diabetes Care"},{"key":"500_CR2","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc14-2441","volume":"38","author":"SE Inzucchi","year":"2015","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140\u20139.","journal-title":"Diabetes Care"},{"key":"500_CR3","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/dom.12054","volume":"15","author":"K Stenlof","year":"2013","unstructured":"Stenlof K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15:372\u201382.","journal-title":"Diabetes Obes Metab"},{"key":"500_CR4","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/dom.12273","volume":"16","author":"T Forst","year":"2014","unstructured":"Forst T, Guthrie R, Goldenberg R, et al. Efficacy and safety of canagliflozin over 52\u00a0weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab. 2014;16:467\u201377.","journal-title":"Diabetes Obes Metab"},{"key":"500_CR5","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1007\/s00125-013-3039-1","volume":"56","author":"FJ Lavalle-Gonzalez","year":"2013","unstructured":"Lavalle-Gonzalez FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013;56:2582\u201392.","journal-title":"Diabetologia"},{"key":"500_CR6","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0140-6736(13)60683-2","volume":"382","author":"WT Cefalu","year":"2013","unstructured":"Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52\u00a0week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;382:941\u201350.","journal-title":"Lancet"},{"key":"500_CR7","unstructured":"Invokana\u00ae (canagliflozin) Full Prescribing Information. Janssen Pharmaceuticals; Titusville, NJ: 2013."},{"key":"500_CR8","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1185\/03007995.2014.982750","volume":"31","author":"EK Buysman","year":"2015","unstructured":"Buysman EK, Chow W, Henk HJ, Rupnow MF. Characteristics and short-term outcomes of patients with type 2 diabetes mellitus treated with canagliflozin in a real-world setting. Curr Med Res Opin. 2015;31:137\u201343.","journal-title":"Curr Med Res Opin"},{"key":"500_CR9","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12902-015-0064-8","volume":"15","author":"EK Buysman","year":"2015","unstructured":"Buysman EK, Chow W, Henk HJ, Rupnow MF. Characteristics and outcomes of patients with type 2 diabetes mellitus treated with canagliflozin: a real-world analysis. BMC Endocr Disord. 2015;15:67.","journal-title":"BMC Endocr Disord"},{"key":"500_CR10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2337\/diaclin.34.1.3","volume":"34","author":"American Diabetes Association","year":"2016","unstructured":"American Diabetes Association. Standards of medical care in diabetes\u20142016 abridged for primary care providers. Clin Diabetes. 2016;34:3\u201321.","journal-title":"Clin Diabetes"},{"key":"500_CR11","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1056\/NEJMc1306652","volume":"369","author":"MK Ali","year":"2013","unstructured":"Ali MK, Bullard KM, Gregg EW. Achievement of goals in US Diabetes Care, 1999\u20132010. New Engl J Med. 2013;369:287\u20138.","journal-title":"New Engl J Med"},{"key":"500_CR12","doi-asserted-by":"crossref","first-page":"363","DOI":"10.18553\/jmcp.2008.14.4.363","volume":"14","author":"S VanDeKoppel","year":"2008","unstructured":"VanDeKoppel S, Choe HM, Sweet BV. Managed care perspective on three new agents for type 2 diabetes. J Manag Care Pharm. 2008;14:363\u201380.","journal-title":"J Manag Care Pharm"},{"key":"500_CR13","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.2337\/dc12-2258","volume":"36","author":"S Stark Casagrande","year":"2013","unstructured":"Stark Casagrande S, Fradkin JE, Saydah SH, Rust KF, Cowie CC. The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988\u20132010. Diabetes Care. 2013;36:2271\u20139.","journal-title":"Diabetes Care"},{"key":"500_CR14","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","volume":"321","author":"IM Stratton","year":"2000","unstructured":"Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405\u201312.","journal-title":"BMJ"},{"key":"500_CR15","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1177\/0145721705274927","volume":"31","author":"MK Rhee","year":"2005","unstructured":"Rhee MK, Slocum W, Ziemer DC, et al. Patient adherence improves glycemic control. Diabetes Educ. 2005;31:240\u201350.","journal-title":"Diabetes Educ"},{"key":"500_CR16","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.diabres.2011.12.003","volume":"96","author":"A Nagrebetsky","year":"2012","unstructured":"Nagrebetsky A, Griffin S, Kinmonth AL, Sutton S, Craven A, Farmer A. Predictors of suboptimal glycaemic control in type 2 diabetes patients: the role of medication adherence and body mass index in the relationship between glycaemia and age. Diabetes Res Clin Pract. 2012;96:119\u201328.","journal-title":"Diabetes Res Clin Pract"},{"key":"500_CR17","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1108\/S0731-2199(2010)0000022010","volume":"22","author":"WE Encinosa","year":"2010","unstructured":"Encinosa WE, Bernard D, Dor A. Does prescription drug adherence reduce hospitalizations and costs? The case of diabetes. Adv Health Econ Health Serv Res. 2010;22:151\u201373.","journal-title":"Adv Health Econ Health Serv Res"},{"key":"500_CR18","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.2337\/diacare.27.5.1218","volume":"27","author":"JA Cramer","year":"2004","unstructured":"Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27:1218\u201324.","journal-title":"Diabetes Care"},{"key":"500_CR19","volume-title":"Proportion of days covered (PDC) as a preferred method of measuring adherence","author":"DP Nau","year":"2012","unstructured":"Nau DP. Proportion of days covered (PDC) as a preferred method of measuring adherence. Springfield: Pharm Qual Alliance; 2012."},{"key":"500_CR20","first-page":"191","volume":"9","author":"K Tunceli","year":"2015","unstructured":"Tunceli K, Zhao C, Davies MJ, et al. Factors associated with adherence to oral antihyperglycemic monotherapy in patients with type 2 diabetes. Patient Prefer Adherence. 2015;9:191\u20137.","journal-title":"Patient Prefer Adherence"},{"key":"500_CR21","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/S1098-3015(10)64171-X","volume":"6","author":"RJA Rajagopalan","year":"2003","unstructured":"Rajagopalan RJA, Smith D, Ollendorf D, Murray FT. Medication compliance in type 2 diabetes patients: retrospective data analysis. Value Health. 2003;6:328.","journal-title":"Value Health"},{"key":"500_CR22","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0149-2918(01)80110-7","volume":"23","author":"G Dailey","year":"2001","unstructured":"Dailey G, Kim MS, Lian JF. Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a medicaid patient population with type 2 diabetes mellitus. Clin Ther. 2001;23:1311\u201320.","journal-title":"Clin Ther"},{"key":"500_CR23","doi-asserted-by":"crossref","first-page":"604","DOI":"10.2337\/dc14-2098","volume":"38","author":"MS Kirkman","year":"2015","unstructured":"Kirkman MS, Rowan-Martin MT, Levin R, et al. Determinants of adherence to diabetes medications: findings from a large pharmacy claims database. Diabetes Care. 2015;38:604\u20139.","journal-title":"Diabetes Care"},{"key":"500_CR24","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.2337\/diacare.24.8.1411","volume":"24","author":"SJ Boccuzzi","year":"2001","unstructured":"Boccuzzi SJ, Wogen J, Fox J, Sung JC, Shah AB, Kim J. Utilization of oral hypoglycemic agents in a drug-insured US population. Diabetes Care. 2001;24:1411\u20135.","journal-title":"Diabetes Care"},{"key":"500_CR25","first-page":"1294","volume":"2014","author":"VJ Zhu","year":"2014","unstructured":"Zhu VJ, Tu W, Rosenman MB, Overhage JM. A comparison of data driven-based measures of adherence to oral hypoglycemic agents in medicaid patients. AMIA Annu Symp Proc. 2014;2014:1294\u2013301.","journal-title":"AMIA Annu Symp Proc"},{"key":"500_CR26","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","volume":"173","author":"H Quan","year":"2011","unstructured":"Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173:676\u201382.","journal-title":"Am J Epidemiol"},{"key":"500_CR27","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1370\/afm.1364","volume":"10","author":"EA Bayliss","year":"2012","unstructured":"Bayliss EA, Ellis JL, Shoup JA, Zeng C, McQuillan DB, Steiner JF. Association of patient-centered outcomes with patient-reported and ICD-9-based morbidity measures. Ann Family Med. 2012;10:126\u201333.","journal-title":"Ann Family Med"},{"key":"500_CR28","first-page":"15","volume":"14","author":"BA Young","year":"2008","unstructured":"Young BA, Lin E, Von Korff M, et al. Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization. Am J Manag Care. 2008;14:15\u201323.","journal-title":"Am J Manag Care"},{"key":"500_CR29","first-page":"721","volume":"18","author":"HY Chang","year":"2012","unstructured":"Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted diabetes complications severity index in claims data. Am J Manag Care. 2012;18:721\u20136.","journal-title":"Am J Manag Care"},{"key":"500_CR30","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Inter Suppl. 2013;3:1\u2013150."},{"key":"500_CR31","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","volume":"11","author":"JA Cramer","year":"2008","unstructured":"Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11:44\u20137.","journal-title":"Value Health"},{"key":"500_CR32","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1056\/NEJMoa1003795","volume":"363","author":"S Zoungas","year":"2010","unstructured":"Zoungas S, Patel A, Chalmers J, et al. Severe hypoglycemia and risks of vascular events and death. New Engl J Med. 2010;363:1410\u20138.","journal-title":"New Engl J Med"},{"key":"500_CR33","first-page":"457","volume":"15","author":"NK Choudhry","year":"2009","unstructured":"Choudhry NK, Shrank WH, Levin RL, et al. Measuring concurrent adherence to multiple related medications. Am J Manag Care. 2009;15:457\u201364.","journal-title":"Am J Manag Care"},{"key":"500_CR34","unstructured":"US Department of Labor, Bureau of Labor Statistics. Consumer Price Index. Medical Care. Series ID: SUUR0000SAM. 2012. http:\/\/data.bls.gov\/cgi-bin\/surveymost?su . Accessed 20 September 2016."},{"key":"500_CR35","unstructured":"Jain R, Cai J, Fu AC, Chow W, Tan H. Real-world (RW) glycemic control and medication adherence among patients with type 2 diabetes mellitus (T2DM) initiated on canagliflozin. 76th ADA Scientific Sessions. Diabetes 2016;65."},{"key":"500_CR36","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1080\/13696998.2016.1208208","volume":"19","author":"J Cai","year":"2016","unstructured":"Cai J, Wang Y, Baser O, Xie L, Chow W. Comparative persistence and adherence with newer anti-hyperglycemic agents to treat patients with type 2 diabetes in the United States. J Med Econ. 2016;19:1175\u201386.","journal-title":"J Med Econ"},{"key":"500_CR37","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1185\/03007995.2015.1047748","volume":"31","author":"LM Meckley","year":"2015","unstructured":"Meckley LM, Miyasato G, Kokkotos F, Bumbaugh J, Bailey RA. An observational study of glycemic control in canagliflozin treated patients. Curr Med Res Opin. 2015;31:1479\u201386.","journal-title":"Curr Med Res Opin"},{"key":"500_CR38","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1080\/03007995.2016.1183604","volume":"32","author":"P Lefebvre","year":"2016","unstructured":"Lefebvre P, Pilon D, Robitaille MN, et al. Real-world glycemic, blood pressure, and weight control in patients with type 2 diabetes mellitus treated with canagliflozin\u2014an electronic health-record-based study. Curr Med Res Opin. 2016;32:1151\u20139.","journal-title":"Curr Med Res Opin"},{"key":"500_CR39","first-page":"s296","volume":"20","author":"RA Bailey","year":"2014","unstructured":"Bailey RA, Vijapurkar U, Meininger GE, Rupnow MF, Blonde L. Diabetes-related quality measure attainment: canagliflozin versus sitagliptin based on a pooled analysis of 2 clinical trials. Am J Mana Care. 2014;20:s296\u2013305.","journal-title":"Am J Mana Care"},{"key":"500_CR40","doi-asserted-by":"crossref","first-page":"130","DOI":"10.18553\/jmcp.2006.12.2.130","volume":"12","author":"JM Stephens","year":"2006","unstructured":"Stephens JM, Botteman MF, Hay JW. Economic impact of antidiabetic medications and glycemic control on managed care organizations: a review of the literature. J Manag Care Pharm. 2006;12:130\u201342.","journal-title":"J Manag Care Pharm"},{"key":"500_CR41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1478-7547-4-1","volume":"4","author":"AK Oglesby","year":"2006","unstructured":"Oglesby AK, Secnik K, Barron J, Al-Zakwani I, Lage MJ. The association between diabetes related medical costs and glycemic control: a retrospective analysis. Cost Effectiveness Resour Alloc. 2006;4:1.","journal-title":"Cost Effectiveness Resour Alloc"},{"key":"500_CR42","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1377\/hlthaff.2011.1198","volume":"31","author":"AK Jha","year":"2012","unstructured":"Jha AK, Aubert RE, Yao J, Teagarden JR, Epstein RS. Greater adherence to diabetes drugs is linked to less hospital use and could save nearly $5 billion annually. Health Aff. 2012;31:1836\u201346.","journal-title":"Health Aff"},{"key":"500_CR43","doi-asserted-by":"crossref","first-page":"E104","DOI":"10.1503\/cmaj.150904","volume":"188","author":"CL Roumie","year":"2016","unstructured":"Roumie CL, Min JY, Greevy RA, et al. Risk of hypoglycemia following intensification of metformin treatment with insulin versus sulfonylurea. CMAJ. 2016;188:E104\u201312.","journal-title":"CMAJ"},{"key":"500_CR44","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1001\/jama.2014.4312","volume":"311","author":"CL Roumie","year":"2014","unstructured":"Roumie CL, Greevy RA, Grijalva CG, et al. Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes. JAMA. 2014;311:2288\u201396.","journal-title":"JAMA"},{"key":"500_CR45","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.2337\/dc10-1915","volume":"34","author":"SS Johnston","year":"2011","unstructured":"Johnston SS, Conner C, Aagren M, Smith DM, Bouchard J, Brett J. Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes. Diabetes Care. 2011;34:1164\u201370.","journal-title":"Diabetes Care"},{"key":"500_CR46","unstructured":"Bloomfield HE, Greer N, Newman D, et al. Predictors and consequences of severe hypoglycemia in adults with diabetes\u2014a systematic review of the evidence. Washington (DC): Department of Veterans Affairs (US). 2012."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-017-0500-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-017-0500-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-017-0500-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T00:35:49Z","timestamp":1658709349000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-017-0500-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,1]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["500"],"URL":"https:\/\/doi.org\/10.1007\/s12325-017-0500-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,1]]}}}